Inovio Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Inovio Pharmaceuticals, Inc.
Finance Watch: Structure Launches Third And Largest US Biopharma IPO Of 2023
Public Company Edition: Structure Therapeutics’ upsized initial public offering raises $161.1m, surpassing proposed terms for up to $134.3m. Also, Pliant capitalizes on good data with a $287.5m follow-on offering, while Magenta seeks strategic alternatives and Instil reveals more job cuts.
Gene Therapy, RNA-Focused Biotechs Lead China December Fundraising
Venture capital and private equity firms pumped a combined $102m into seven Chinese biotechs in major deals announced during December.
Verona Emerges Victorious From Second COPD Trial
After once again showing significant improvements in lung function and a 36% reduction in rate of exacerbations over 24 weeks, Verona is confident that its dual PDE3/4 inhibitor will change the treatment paradigm for COPD.
Medtech 100: Big Three Companies Lead From The Front With Medtech Back On Solid Growth Footing
Abbott Laboratories and Johnson & Johnson joined Medtronic in putting a clear distance between themselves and other global medtechs in the Top 10 by revenues for 2021. Post-COVID-19 procedure growth, and, for Abbott, a strong rebound in non-COVID diagnostic demand, were key drivers.
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- Bioject Medical Technologies
- Inovio Biomedical
- VGX Pharmaceuticals
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.